Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 75498-96-3 Chemical Structure| 75498-96-3

Structure of Cefminox sodium
CAS No.: 75498-96-3

Chemical Structure| 75498-96-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cefminox Sodium (MT-141), the sodium salt form of cefminox, is a semi-synthetic cephalosporin with antibacterial activity.

Synonyms: MT-141; Meicelin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cefminox sodium

CAS No. :75498-96-3
Formula : C16H20N7NaO7S3
M.W : 541.55
SMILES Code : O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSC[C@@H](N)C(O)=O)=O)C1=O)[O-].[Na+]
Synonyms :
MT-141; Meicelin
MDL No. :MFCD00941387

Safety of Cefminox sodium

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H315-H319
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Escherichia coli S31 1-2 mg/liter 20 h Evaluate the bacteriolytic activity of Cefminox against E. coli, showing lysis at concentrations close to the MIC. Antimicrob Agents Chemother. 1992 Jan;36(1):223-6
Escherichia coli ATCC25922 2 mg/liter 20 h Evaluate the bacteriolytic activity of Cefminox against E. coli, showing lysis at concentrations close to the MIC. Antimicrob Agents Chemother. 1992 Jan;36(1):223-6
Clostridium difficile 2.0–4.0 μg/ml 48 h To evaluate the antibacterial activity of cefminox against Clostridium difficile, results showed MIC50 of 2.0 μg/ml and MIC90 of 2.0 μg/ml. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501
Peptostreptococcus anaerobius 0.125–4.0 μg/ml 48 h To evaluate the antibacterial activity of cefminox against Peptostreptococcus anaerobius, results showed MIC50 of 1.0 μg/ml and MIC90 of 2.0 μg/ml. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501
Fusobacterium necrophorum 0.06–1 μg/ml 48 h To evaluate the antibacterial activity of cefminox against Fusobacterium necrophorum, results showed MIC50 of 0.25 μg/ml and MIC90 of 0.25 μg/ml. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501
Bacteroides thetaiotaomicron 2.0–128.0 μg/ml 48 h To evaluate the antibacterial activity of cefminox against Bacteroides thetaiotaomicron, results showed MIC50 of 4.0 μg/ml and MIC90 of 4.0 μg/ml. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501
Bacteroides fragilis 0.25–128.0 μg/ml 48 h To evaluate the antibacterial activity of cefminox against Bacteroides fragilis, results showed MIC50 of 1.0 μg/ml and MIC90 of 2.0 μg/ml. Antimicrob Agents Chemother. 1998 Mar;42(3):495-501
Primary rat pulmonary artery smooth muscle cells 0-500 µM 48 h To evaluate the inhibitory effect of cefminox on cell growth, results showed cefminox significantly inhibited hypoxia-induced PASMC proliferation Front Pharmacol. 2018 Feb 23;9:134

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats Hypoxia-induced pulmonary hypertension model Tail intravenous injection 160 mg/kg and 320 mg/kg Once daily for 28 days To evaluate the therapeutic efficacy of cefminox on pulmonary hypertension, results showed cefminox significantly reduced mean pulmonary artery pressure and inhibited right ventricular remodeling Front Pharmacol. 2018 Feb 23;9:134

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.18mL

9.23mL

1.85mL

0.92mL

18.47mL

3.69mL

1.85mL

References

 

Historical Records

Categories